Myriad Loses Appeals Court Bid to Block Breast Cancer Tests

Posted by BernardSwiss on Dec 19, 2014 7:31 AM EDT
Bloomberg; By Susan Decker
Mail this story
Print this story

Myriad Genetics Inc. (MYGN) can’t block competitors’ DNA tests to determine risk for breast and ovarian cancer after a U.S. appeals court said three patents on the tests never should have been issued.

The patents cover products of nature and ideas that aren’t eligible for legal protection, the U.S. Court of Appeals for the Federal Circuit said in an opinion posted today on the court’s docket. The court upheld a trial judge’s decision to allow the competing tests, including those made by Ambry Genetics Corp., to remain on the market.

Full Story

  Nav
» Read more about: Story Type: News Story; Groups: Intellectual Property, Standards

« Return to the newswire homepage

This topic does not have any threads posted yet!

You cannot post until you login.